Publications by authors named "Ruiyang Xie"
Cisplatin-based chemotherapy is the recommended therapy for muscle-invasive bladder cancer (MIBC). However, the efficacy of MIBC for chemotherapy is only about 40%. Therefore, predictors of therapy response are urgently needed.
View Article and Find Full Text PDFBackground And Objective: Systemic treatments involving immunotherapy-tyrosine kinase inhibitor (IO-TKI) combinations and TKI monotherapy have significantly improved outcomes for patients with metastatic clear-cell renal cell carcinoma (mccRCC). However, there are no biomarkers for predicting the efficacy of these treatments. Our aim was to investigate the prognostic and therapeutic significance of serum immunoglobulin G (IgG) in patients with mccRCC patients receiving systemic therapy.
View Article and Find Full Text PDFArticle Synopsis
- Desmoid tumors (DT) are rare, invasive tumors that are shifting from surgical treatment to systemic therapies due to their effectiveness and safety, highlighting the need for a solid first-line treatment option.
- A systematic review and network meta-analysis evaluated multiple systemic treatments for DT, analyzing data from 295 patients to compare their efficacy and safety.
- Results indicated that the γ-secretase inhibitor showed superior tumor control, while chemotherapy and TKIs provided improved long-term survival, with TKIs demonstrating fewer side effects.*
Article Synopsis
- CAR-T therapy has improved treatment options for relapsed/refractory B-cell lymphoblastic leukemia, but it can cause serious side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- A study involving 93 patients showed that while most (81.7%) experienced CRS and a few (5.3%) experienced ICANS, these conditions did not significantly impact treatment effectiveness or patient survival rates.
- Ultimately, the findings suggest that experiencing CRS or ICANS does not lead to worse outcomes for patients receiving anti-CD19 CAR-T therapy.
Objectives: Previous studies have been inconsistent concerning the association between the prognostic value of CD30 expression and extranodal natural killer/T-cell lymphoma (ENKTL).
Methods: CD30 expression in 82 patients with newly diagnosed ENKTL (mean age, 50 years; 73.2% male) was assessed by immunohistochemistry on paraffin-embedded sections.
Background: By prolonging overall survival and reducing disease recurrence rates, immune checkpoint inhibitors (ICIs) are an emerging adjuvant therapy option for patients with resectable malignant tumors. However, the safety profile (deaths and adverse events [AEs]) of adjuvant ICIs has not been fully described.
Methods: We searched the literature for phase III randomized clinical trials that compared PD-1, PD-L1, and CTLA-4 inhibitors in solid malignant tumors.
Background: The efficacy of systemic therapy regimens, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (IO-TKI) and targeted therapy, for metastatic clear cell renal cell carcinoma (ccRCC) remains unpredictable due to the lack of effective biomarkers. Neutrophil extracellular trap (NET) plays an important role in promoting ccRCC. This study explores the NET predictive value of the efficacy in metastatic ccRCC.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) combined with chemotherapy are being studied as a treatment for advanced gastrointestinal cancers, but the risk of blood-related side effects is still not fully understood.
- A phase 3 meta-analysis examined data from 16 clinical trials with 9,732 patients and found that treatment-related deaths were rare, with hematologic deaths accounting for only 0.13%.
- Nivolumab plus chemotherapy showed a higher risk of severe adverse events compared to other treatments, while ICIs used alone generally resulted in fewer blood-related side effects than chemotherapy regimens.
In addition to the anti-infection response, neutrophils are linked to tumor progression through the secretion of inflammation components and neutrophil extracellular traps (NETs) formation. NET is a web-like structure constituted by a chromatin scaffold coated with specific nuclear and cytoplasmic proteins, such as histone and granule peptides. Increasing evidence has demonstrated that NETs are favorable factors to promote tumor growth, invasion, migration, and immunosuppression.
View Article and Find Full Text PDFObjective: For patients with advanced or metastatic renal cell carcinoma (RCC), the dose of targeted agents was recommended in combination with immune checkpoint inhibitors. We performed a network meta-analysis to describe a categorized safety ranking profile and assess the adaptability of the combination options of targeted agents.
Methods: The targeted agents refer to vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) and mammalian target of rapamycin (mTOR) inhibitors.
Article Synopsis
- The study looked at immune cells in muscle-invasive bladder cancer before and after treatment with chemotherapy to see how they change and what that means for patients.
- Researchers tested different types of immune cells in 54 patients' tissues and found that certain cells called TAMs decreased after treatment.
- They discovered that higher levels of these TAMs might mean a patient could have a worse chance of staying cancer-free after treatment, but they couldn't use other immune cells to predict how well patients would respond to chemotherapy.
Hypothesis: Nomogram can be built to predict the pathological T3a upstaging from clinical T1a in patients with localized renal cell carcinoma before surgery.
Purpose: Renal cell carcinoma (RCC) patients with clinical T1a (cT1a) disease who are upstaged to pathological T3a (pT3a) have reduced survivals after partial nephrectomy. We aimed to develop a nomogram-based model predicting pT3a upstaging in RCC patients with preoperative cT1a based on multiple preoperative blood indexes and oncological characteristics.
Background: The transmembrane transporter Sema3D is a vital molecule involved in axon guidance and carcinogenesis of variant malignancies. However, the relationship between Sema3D and clear cell renal cell carcinoma (ccRCC) is barely reported and remains unclear.
Methods: Sema3D expression and the connection of clinical and histological characteristics were first analyzed with transcriptome data in the TCGA repository.
Muscle-invasive bladder cancer (MIBC) is an aggressive disease requiring active management. Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is considered the standard treatment paradigm for MIBC patients, which could result in significant perioperative mortality and morbidity, as well as the significant alteration of the quality of life (QOL). Notably, multimodal bladder-preserving treatment strategies have been recommended for highly selected patients.
View Article and Find Full Text PDFBackground: Non-metastatic renal cell carcinoma (RCC) with tumor thrombus showed a greater tendency for developing metastases after surgery. Early identification of patients with high risk of poor prognosis is especially important to explore adjuvant treatment of improving outcomes. Neutrophil-to-lymphocyte ratio (NLR) was a systemic inflammation marker and outcome predictor in RCC, reflecting the chaos in systemic immune status in cancer as myeloid cell expansion and lymphatic cell suppression.
View Article and Find Full Text PDFObjectives: Metastatic renal cell carcinoma can occur synchronously or metachronously. We characterized the time from diagnosis to systematic therapy as a categorical variable to analyze its effect on the overall survival and first-line treatment efficacy of metastatic renal cell carcinoma patients.
Methods: We initially enrolled 949 consecutive metastatic renal cell carcinoma patients treated with targeted therapies retrospectively from December 2005 to December 2019.
Background: Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a network meta-analysis was conducted.
Methods: A total of 5948 studies were screened and 13 randomized controlled trials with 1939 patients, of whom 1106 patients received OV therapies, comparing four OVs (NTX-010, pexastimogene devacirepvec (Pexa-Vec), talimogene laherparepvec (T-VEC), and pelareorep) were included in a Bayesian network meta-analysis.
At present, prostate cancer radical surgery still lacks an objective standard for predicting the anatomic difficulty of surgery through preoperative examination. Due to the poor prognosis and surgical complications caused by "Narrow Pelvis," a pelvic model for prediction is urgently needed. The purpose of this study is to present objective preoperative assessing indicators to predict the surgical difficulty caused by pelvic anatomic abnormalities during laparoscopic radical prostatectomy (LRP).
View Article and Find Full Text PDF